New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
The firm said total revenues rose to $461.4 million from $431.7 million in the first quarter of 2018, beating analysts' consensus estimate of $450.1 million.
Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.
The firm said the purchase will allow it to better provide software tools to customers in the chemistry, pharmaceutical, and analytical laboratory markets.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
